American Regent vs. Apotex: Trace Elements Drug Patent Case Consolidated in New Jersey
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | American Regent, Inc. v. Apotex Inc. |
| Numéro de dossier | 2:24-cv-02268 (D.N.J.) |
| Tribunal | Tribunal fédéral de première instance pour le district du New Jersey |
| Durée | March 2024 – July 2024 114 days |
| Résultat | Consolidated (Lead Case: 24-1022) |
| Brevets en cause | |
| Produits incriminés | Apotex Trace Elements Injection Products |
Aperçu du dossier
Les parties
⚖️ Demandeur
U.S.-based pharmaceutical company with a focused portfolio in injectable drug products, including specialty and critical-care formulations. ARI holds commercial rights to Multrys® and Tralement®.
🛡️ Défendeur
Canadian generic pharmaceutical manufacturer, one of North America’s largest producers of generic drugs. Its U.S. commercial arm, Apotex Corp., distributes generic formulations.
Le brevet en cause
This landmark case involved U.S. Patent No. US11786548B2 (application number US17/365695), covering technology in the pharmaceutical formulation space — specifically relating to trace elements injection products. Trace elements injections containing zinc, copper, manganese, and selenium (the four-element formulation designated as “4*”) are used in parenteral nutrition protocols for hospitalized patients, making this a clinically significant and commercially valuable category.
Vous développez une formulation médicamenteuse similaire ?
Check if your pharmaceutical product might infringe this or related patents before launch.
Le verdict et l'analyse juridique
Résultat
This case was closed via consolidation rather than through trial, summary judgment, or settlement. The court’s order consolidated Civil Action Nos. 24-1022, 24-1030, 24-1169, and 24-2268 into a single proceeding maintained under Case No. 24-1022. All future filings and proceedings for the Apotex defendants are now governed within that consolidated matter. No damages were awarded, no injunctive relief was entered, and no claim construction rulings issued in this specific docket prior to consolidation.
Principales questions juridiques
The court’s order granted a joint request by all parties, finding “good cause” to merge the related actions. This procedural alignment is significant: it suggests that the underlying patent claims, accused products, and legal theories across all four actions share sufficient commonality to warrant unified management. In multi-defendant pharmaceutical patent litigation, consolidation eliminates the risk of inconsistent claim constructions across parallel proceedings, reduces duplicative discovery, and streamlines expert testimony on technical issues — particularly critical when the patent at issue involves complex pharmaceutical formulation chemistry. This setup allows for a single Markman hearing to produce a unified claim construction binding on all defendants, a key strategic benefit.
Freedom to Operate (FTO) Analysis in Pharmaceutical Injectables
Ce cas met en évidence les risques critiques liés à la propriété intellectuelle dans la formulation pharmaceutique. Choisissez la prochaine étape :
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View related patents and their claim scope in the trace elements space
- See which companies are active in injectable drug formulations
- Understand claim construction implications from consolidation
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la formulation de votre médicament ou ses caractéristiques techniques.
- L'IA identifie les brevets pharmaceutiques susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Injectable drug formulations (e.g., trace elements)
1 Patent (Consolidated)
US11786548B2 is central to 4 cases
Hatch-Waxman Implications
Monitor 30-month stays and FDA timelines
✅ Points clés à retenir
Multi-defendant consolidation in pharmaceutical patent litigation streamlines Markman proceedings but requires careful co-defendant coordination on invalidity and non-infringement positions.
Rechercher la jurisprudence connexe →New Jersey District Court remains a premier venue for pharmaceutical patent actions; strategic venue selection here reflects established pharmaceutical litigation infrastructure.
Explorer les précédents →The ‘548 patent (US11786548B2) and its claim scope will be central to the consolidated proceeding — monitor docket 24-1022 for claim construction developments.
Suivre le statut d'un brevet →Foire aux questions
The case involves U.S. Patent No. US11786548B2 (application no. US17/365695), covering technology related to trace elements injection 4*, USP formulations.
The case was not resolved on the merits. It was consolidated with three related ARI actions — Case Nos. 24-1022, 24-1030, and 24-1169 — into a single lead proceeding under Civil Action No. 24-1022 in the District of New Jersey.
A unified claim construction ruling in the consolidated proceeding will define the enforceable scope of the ‘548 patent against all named generic defendants simultaneously, making the Markman hearing in Case No. 24-1022 a critical watch point for the industry.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER Docket — Case No. 2:24-cv-02268
- USPTO Patent Center — US11786548B2
- Cornell Legal Information Institute — Hatch-Waxman Act Overview
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.